NSE / BSEHealthcare
β‚Ή2412.25+0.00+0.00%
P/E41.5Mkt Capβ‚Ή29.22 K CrEV/EBITDA32.1

J.B. Chemicals & Pharmaceuticals Lt

P/E41.5Mkt Capβ‚Ή29.22 K CrEV/EBITDA32.1
Company Profile

J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, and capsules; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, the company offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners; and contract manufacturing services. It provides its products to gastroenterology, anti-infectives, wound care, neonatology and pediatrics, gynaecology, dental, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-analgesic, dermatology, antivirals, lozenges, and contrast media and radio diagnostic therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Mumbai, India.

Valuation

Market Cap
β‚Ή0.00
β€”
Current Price
β‚Ή0
β€”as of 17 Jul 2026
P/E Ratio
0.0x
β€”
P/B Ratio
0.0x
β€”
EV / EBITDA
0.0x
β€”
EV / Sales
0.0x
β€”
52W High
β‚Ή0
β€”
52W Low
β‚Ή0
β€”
Shares Out
0.00 Cr
β€”

Profitability

Operating Margin
0.0%
β€”
Net Profit Margin
0.0%
β€”
EBITDA Margin
0.0%
β€”

Returns

ROE
0.0%
β€”
ROCE
0.0%
β€”
ROIC %
β€”
β€”
ROA
0.0%
β€”
Dividend Payout
0.0%
β€”

Solvency

Current Ratio
0.0x
β€”
Debt / Equity
0.0x
β€”
Debt / Assets
0.0x
β€”
CFO / Net Profit
0.0x
β€”
Interest Coverage
0.0x
β€”

AI Summary

Indian Stock

Sign up free to view AI insights

Get Started

Rule-based from financial data. Not advice.

Price Historyβ–² 44.95% over 1Y
Monthly Returns

Historically, Jul has averaged the highest return (+7.9%); Feb the lowest (-3.3%).

Average from:
YearJanFebMarAprMayJunJulAugSepOctNovDec
2026+2.7%Positive MonthJan 2026: +2.73%+9.8%Positive MonthFeb 2026: +9.77%+0.5%Neutral MonthMar 2026: +0.50%-0.7%Neutral MonthApr 2026: -0.73%+6.1%Positive MonthMay 2026: +6.07%+5.7%Positive MonthJun 2026: +5.66%+5.1%*Positive MonthJul 2026: +5.09%β€”β€”β€”β€”β€”
2025-4.6%Negative MonthJan 2025: -4.62%-6.4%Negative MonthFeb 2025: -6.44%-1.5%Neutral MonthMar 2025: -1.45%-0.7%Neutral MonthApr 2025: -0.74%+4.3%Positive MonthMay 2025: +4.35%-0.0%Neutral MonthJun 2025: -0.03%+5.2%Positive MonthJul 2025: +5.22%-2.4%Negative MonthAug 2025: -2.40%-1.0%Neutral MonthSep 2025: -0.99%-1.6%Neutral MonthOct 2025: -1.62%+5.4%Positive MonthNov 2025: +5.39%+2.8%Positive MonthDec 2025: +2.81%
2024+3.5%Positive MonthJan 2024: +3.46%-7.4%Negative MonthFeb 2024: -7.37%+6.0%Positive MonthMar 2024: +5.96%+15.4%Positive MonthApr 2024: +15.44%-7.3%Negative MonthMay 2024: -7.34%-0.5%Neutral MonthJun 2024: -0.46%+9.6%Positive MonthJul 2024: +9.62%+1.3%Neutral MonthAug 2024: +1.29%-3.8%Negative MonthSep 2024: -3.81%+4.3%Positive MonthOct 2024: +4.33%-11.3%Negative MonthNov 2024: -11.32%+6.3%Positive MonthDec 2024: +6.31%
2023+5.1%Positive MonthJan 2023: +5.09%-5.3%Negative MonthFeb 2023: -5.31%+1.9%Neutral MonthMar 2023: +1.91%+8.1%Positive MonthApr 2023: +8.12%-1.4%Neutral MonthMay 2023: -1.37%+12.6%Positive MonthJun 2023: +12.60%+5.5%Positive MonthJul 2023: +5.50%+10.8%Positive MonthAug 2023: +10.76%+7.3%Positive MonthSep 2023: +7.30%-5.7%Negative MonthOct 2023: -5.73%+4.1%Positive MonthNov 2023: +4.13%+11.5%Positive MonthDec 2023: +11.54%
2022-2.2%Negative MonthJan 2022: -2.21%-7.0%Negative MonthFeb 2022: -7.00%-2.6%Negative MonthMar 2022: -2.57%+9.6%Positive MonthApr 2022: +9.64%-5.8%Negative MonthMay 2022: -5.85%-3.5%Negative MonthJun 2022: -3.52%+12.8%Positive MonthJul 2022: +12.78%+0.3%Neutral MonthAug 2022: +0.26%+8.1%Positive MonthSep 2022: +8.09%+3.0%Positive MonthOct 2022: +2.96%+1.9%Neutral MonthNov 2022: +1.91%-3.4%Negative MonthDec 2022: -3.40%
2021β€”β€”β€”β€”β€”+16.3%Positive MonthJun 2021: +16.27%+9.1%Positive MonthJul 2021: +9.05%-6.1%Negative MonthAug 2021: -6.15%+9.6%Positive MonthSep 2021: +9.58%-10.1%Negative MonthOct 2021: -10.10%-2.3%Negative MonthNov 2021: -2.29%+8.5%Positive MonthDec 2021: +8.50%
AvgΒ±SD+0.9%Β±3.7%-3.3%Β±6.6%+0.9%Β±3.0%+6.3%Β±6.3%-0.8%Β±5.3%+5.1%Β±7.2%+7.9%Β±2.9%+0.8%Β±5.6%+4.0%Β±5.4%-2.0%Β±5.4%-0.4%Β±6.0%+5.2%Β±5.1%
* Current month β€” value will change until month-end.

Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β€” the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.

Seasonal Tendency

This aggregates every month by calendar position β€” all Januaries together, all Februaries together, and so on β€” to show whether a given month has leaned positive or negative historically. β€˜Simple’ counts each month as +1 or βˆ’1. β€˜Weighted’ gives larger moves more influence: +2 above +10%, βˆ’2 below βˆ’10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations β€” read it as a historical tendency, not a reliable seasonal pattern.

Historical Trend

This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.

Year-to-Date ROI
Average from:
SD Γ—
Latest: 1.325x (2026)

Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β€” at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in β€œAverage from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.

Historical Performance

Revenue, profitability, and cash flow trends (β‚Ή Crores)

Revenue (10Y)

Operating Income (10Y)

Net Profit (10Y)

Operating Margin % (10Y)

Dividend Payout % (10Y)

Free Cash Flow (10Y)

Growth Summary

Latest fiscal year: Mar 2025

Revenueβ‚Ή3.72 K Crβ–² 12.9%
EBITDA Growthβ€”
Net Profitβ‚Ή653.00 Crβ–² 20.3%
Cash from Ops (CFO)β€”
Free Cash Flow (FCF)β€”β–² 900.0%
Revenue CAGR 5Y15.0%
EBITDA CAGR 5Y17.6%
Net Profit CAGR 5Y15.2%
NP Growth 1Y20.3%

Historical Growth

Year-by-year revenue, profitability, and cash flow (β‚Ή Crores, last 10 years)

YearRevenueOp. IncomeNet ProfitCFOFCFROERev Growth 1YNP Growth 1Y
Mar 2025β‚Ή3.72 K Crβ€”β‚Ή653.00 Crβ€”β€”19.3%12.9%20.3%
Mar 2024β‚Ή3.30 K Crβ€”β‚Ή543.00 Crβ€”β€”18.8%14.4%39.6%
Mar 2023β‚Ή2.88 K Crβ€”β‚Ή389.00 Crβ€”β€”15.9%31.7%7.8%
Mar 2022β‚Ή2.19 K Crβ€”β‚Ή361.00 Crβ€”β€”17.2%15.8%-19.2%
Mar 2021β‚Ή1.89 K Crβ€”β‚Ή447.00 Crβ€”β€”24.8%15.3%66.8%
Mar 2020β‚Ή1.64 K Crβ€”β‚Ή268.00 Crβ€”β€”18.5%9.3%47.3%
Mar 2019β‚Ή1.50 K Crβ€”β‚Ή182.00 Crβ€”β€”12.3%20.1%42.2%
Mar 2018β‚Ή1.25 K Crβ€”β‚Ή128.00 Crβ€”β€”8.8%6.4%-26.0%
Mar 2017β‚Ή1.18 K Crβ€”β‚Ή173.00 Crβ€”β€”12.5%2.7%-3.4%
Mar 2016β‚Ή1.14 K Crβ€”β‚Ή179.00 Crβ€”β€”14.6%7.8%57.0%

Financial Statements

Income statement, balance sheet, and cash flow (β‚Ή Crores, as reported)

Consolidated Figures in USD Millions.

Unnamed: 0Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Revenue / Net Sales9571,0611,1441,1751,2501,5011,6411,8922,1902,8843,2993,7233,877
Total Expenses8028689179521,0501,2091,2701,3401,6812,2192,4192,7052,810
EBIT / Operating Profit1541932262221992923705525096658801,0181,068
OPM %16%18%20%19%16%19%23%29%23%23%27%27%28%
Other Income-27105546393737116399343549
Finance Costs6710535375344194
Depreciation & Amortisation273840465655656771112135166170
Profit Before Tax94159231217179269340594471527738877942
Tax %27%29%22%20%29%32%21%25%23%26%26%26%-
Net Profit / PAT68114179173128182268447361389543653704
EPS (β‚Ή)4.046.7010.5710.207.6611.3417.3428.9223.3525.1235.0141.9245.15
Dividend Payout %37%105%24%5%13%22%32%29%35%35%35%37%-

Peer Comparison

Healthcare sector peers, ranked by market cap

CompanyMarket CapRevenueP/EP/BEV/EBITDARev G 1Y
J.B. Chemicals & Pharmaceuticals Ltthis co.β‚Ή29.22 K Crβ‚Ή3.72 K Cr41.507.8532.0612.9%
Sun Pharmaceutical Industries Ltd.β‚Ή4.15 L Crβ‚Ή23.00 K Cr88.7017.4372.3013.5%
Divi's Laboratories Ltd.β‚Ή1.71 L Crβ‚Ή9.20 K Cr67.9011.1367.2120.0%
Torrent Pharmaceuticals Ltd.β‚Ή1.33 L Crβ‚Ή9.68 K Cr62.5015.7645.6413.5%
Cipla Ltd.β‚Ή1.17 L Crβ‚Ή19.05 K Cr22.503.5119.3314.9%
Apollo Hospitals Enterprises Ltd.β‚Ή1.05 L Crβ‚Ή8.20 K Cr75.0011.2854.4412.8%
Max Healthcare Institute Limitedβ‚Ή1.00 L Crβ‚Ή2.66 K Cr144.0011.7696.8413.8%
Industry Averageβ€”β‚Ή3.29 K Cr98.638.1165.5020.2%

Learn while you research

Hand-picked academy chapters to deepen your understanding of J.B. Chemicals & Pharmaceuticals Lt and the metrics that matter.

Browse the full Equiscale Academy